FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295125684> ?p ?o ?g. }

• W4295125684 endingPage "413" @default.
• W4295125684 startingPage "404" @default.
• W4295125684 abstract "Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there is no widely used definition of remission that is stringent but achievable and could be applied uniformly as an outcome measure in clinical trials. This work was undertaken to develop such a definition. Methods A committee consisting of members of the American College of Rheumatology, the European League Against Rheumatism, and the Outcome Measures in Rheumatology Initiative met to guide the process and review prespecified analyses from RA clinical trials. The committee requested a stringent definition (little, if any, active disease) and decided to use core set measures including, as a minimum, joint counts and levels of an acute-phase reactant to define remission. Members were surveyed to select the level of each core set measure that would be consistent with remission. Candidate definitions of remission were tested, including those that constituted a number of individual measures of remission (Boolean approach) as well as definitions using disease activity indexes. To select a definition of remission, trial data were analysed to examine the added contribution of patient-reported outcomes and the ability of candidate measures to predict later good radiographic and functional outcomes. Results Survey results for the definition of remission suggested indexes at published thresholds and a count of core set measures, with each measure scored as 1 or less (eg, tender and swollen joint counts, C reactive protein (CRP) level, and global assessments on a 0–10 scale). Analyses suggested the need to include a patient-reported measure. Examination of 2-year follow-up data suggested that many candidate definitions performed comparably in terms of predicting later good radiographic and functional outcomes, although 28-joint Disease Activity Score–based measures of remission did not predict good radiographic outcomes as well as the other candidate definitions did. Given these and other considerations, we propose that a patient's RA can be defined as being in remission based on one of two definitions: (1) when scores on the tender joint count, swollen joint count, CRP (in mg/dl), and patient global assessment (0–10 scale) are all ≤1, or (2) when the score on the Simplified Disease Activity Index is ≤3.3. Conclusion We propose two new definitions of remission, both of which can be uniformly applied and widely used in RA clinical trials. The authors recommend that one of these be selected as an outcome measure in each trial and that the results on both be reported for each trial." @default.
• W4295125684 created "2022-09-11" @default.
• W4295125684 creator A5000282057 @default.
• W4295125684 creator A5008067100 @default.
• W4295125684 creator A5008811878 @default.
• W4295125684 creator A5012283576 @default.
• W4295125684 creator A5015051319 @default.
• W4295125684 creator A5015727845 @default.
• W4295125684 creator A5018678002 @default.
• W4295125684 creator A5019546428 @default.
• W4295125684 creator A5022067453 @default.
• W4295125684 creator A5022420084 @default.
• W4295125684 creator A5026614224 @default.
• W4295125684 creator A5030544708 @default.
• W4295125684 creator A5031527554 @default.
• W4295125684 creator A5032375376 @default.
• W4295125684 creator A5035644440 @default.
• W4295125684 creator A5035671675 @default.
• W4295125684 creator A5036506240 @default.
• W4295125684 creator A5039032334 @default.
• W4295125684 creator A5042617054 @default.
• W4295125684 creator A5044067217 @default.
• W4295125684 creator A5044290696 @default.
• W4295125684 creator A5044831604 @default.
• W4295125684 creator A5045047976 @default.
• W4295125684 creator A5052078671 @default.
• W4295125684 creator A5058802040 @default.
• W4295125684 creator A5059395553 @default.
• W4295125684 creator A5060191728 @default.
• W4295125684 creator A5060776202 @default.
• W4295125684 creator A5061411814 @default.
• W4295125684 creator A5064101830 @default.
• W4295125684 creator A5065394113 @default.
• W4295125684 creator A5066602987 @default.
• W4295125684 creator A5067962806 @default.
• W4295125684 creator A5068412969 @default.
• W4295125684 creator A5068692530 @default.
• W4295125684 creator A5071926023 @default.
• W4295125684 creator A5073269240 @default.
• W4295125684 creator A5077099389 @default.
• W4295125684 creator A5080646462 @default.
• W4295125684 creator A5084362791 @default.
• W4295125684 creator A5084884266 @default.
• W4295125684 creator A5087130917 @default.
• W4295125684 creator A5087655468 @default.
• W4295125684 creator A5089158758 @default.
• W4295125684 date "2011-02-03" @default.
• W4295125684 modified "2023-10-18" @default.
• W4295125684 title "American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials" @default.
• W4295125684 doi "https://doi.org/10.1136/ard.2011.149765" @default.
• W4295125684 hasPublicationYear "2011" @default.
• W4295125684 type Work @default.
• W4295125684 citedByCount "525" @default.
• W4295125684 countsByYear W42951256842012 @default.
• W4295125684 countsByYear W42951256842013 @default.
• W4295125684 countsByYear W42951256842014 @default.
• W4295125684 countsByYear W42951256842015 @default.
• W4295125684 countsByYear W42951256842016 @default.
• W4295125684 countsByYear W42951256842017 @default.
• W4295125684 countsByYear W42951256842018 @default.
• W4295125684 countsByYear W42951256842019 @default.
• W4295125684 countsByYear W42951256842020 @default.
• W4295125684 countsByYear W42951256842021 @default.
• W4295125684 countsByYear W42951256842022 @default.
• W4295125684 countsByYear W42951256842023 @default.
• W4295125684 crossrefType "journal-article" @default.
• W4295125684 hasAuthorship W4295125684A5000282057 @default.
• W4295125684 hasAuthorship W4295125684A5008067100 @default.
• W4295125684 hasAuthorship W4295125684A5008811878 @default.
• W4295125684 hasAuthorship W4295125684A5012283576 @default.
• W4295125684 hasAuthorship W4295125684A5015051319 @default.
• W4295125684 hasAuthorship W4295125684A5015727845 @default.
• W4295125684 hasAuthorship W4295125684A5018678002 @default.
• W4295125684 hasAuthorship W4295125684A5019546428 @default.
• W4295125684 hasAuthorship W4295125684A5022067453 @default.
• W4295125684 hasAuthorship W4295125684A5022420084 @default.
• W4295125684 hasAuthorship W4295125684A5026614224 @default.
• W4295125684 hasAuthorship W4295125684A5030544708 @default.
• W4295125684 hasAuthorship W4295125684A5031527554 @default.
• W4295125684 hasAuthorship W4295125684A5032375376 @default.
• W4295125684 hasAuthorship W4295125684A5035644440 @default.
• W4295125684 hasAuthorship W4295125684A5035671675 @default.
• W4295125684 hasAuthorship W4295125684A5036506240 @default.
• W4295125684 hasAuthorship W4295125684A5039032334 @default.
• W4295125684 hasAuthorship W4295125684A5042617054 @default.
• W4295125684 hasAuthorship W4295125684A5044067217 @default.
• W4295125684 hasAuthorship W4295125684A5044290696 @default.
• W4295125684 hasAuthorship W4295125684A5044831604 @default.
• W4295125684 hasAuthorship W4295125684A5045047976 @default.
• W4295125684 hasAuthorship W4295125684A5052078671 @default.
• W4295125684 hasAuthorship W4295125684A5058802040 @default.
• W4295125684 hasAuthorship W4295125684A5059395553 @default.
• W4295125684 hasAuthorship W4295125684A5060191728 @default.
• W4295125684 hasAuthorship W4295125684A5060776202 @default.
• W4295125684 hasAuthorship W4295125684A5061411814 @default.
• W4295125684 hasAuthorship W4295125684A5064101830 @default.
• W4295125684 hasAuthorship W4295125684A5065394113 @default.
• W4295125684 hasAuthorship W4295125684A5066602987 @default.

• next